Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Below 200-Day Moving Average – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.77 and traded as low as $9.64. Astellas Pharma shares last traded at $9.71, with a volume of 89,294 shares.

Astellas Pharma Stock Down 0.6 %

The company has a market capitalization of $17.57 billion, a price-to-earnings ratio of -44.13 and a beta of 0.34. The stock’s fifty day simple moving average is $9.62 and its two-hundred day simple moving average is $10.76. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. On average, sell-side analysts predict that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.